atai Life Sciences Q2 EPS $(0.36), Down From $(0.21) Last Year; License Revenue $273K, Up From $172K Prior Year
Portfolio Pulse from Benzinga Newsdesk
atai Life Sciences reported a Q2 EPS of $(0.36), down from $(0.21) last year. License revenue increased to $273K from $172K in the prior year.
August 13, 2024 | 11:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
atai Life Sciences reported a significant decline in Q2 EPS to $(0.36) from $(0.21) last year, indicating increased losses. However, license revenue showed a positive trend, increasing to $273K from $172K.
The significant decline in EPS suggests increased losses, which is a negative indicator for investors. The increase in license revenue is a positive sign but may not be enough to offset concerns about profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100